We're back on Morning Trade Live. Let's focus on Nova Nordics. The stock was downgraded today at Morgan Stanley.More on that coming up in a bit. The weight loss drug trade has lost some luster. Check out this comparison chart of Nova Nordisk and Eli Liy over the past year.Both stocks are down over the last 12 months. Novo down more than 35% during that time frame. And that is the focus of the morning trade.Joining us now for a closer look at Nova Nordisk is Schwab network host Marley Kaden. Very good mornin ...

Group 1 - European stock markets experienced a slight increase, with the healthcare sector being a major support factor [1] - Novo Nordisk's weight loss drug Wegovy demonstrated superior heart protection effects compared to Eli Lilly's competing products, leading to a nearly 3% rise in its stock price [1] - Wegovy was shown to reduce the risk of heart attack, stroke, or death by 57% compared to Eli Lilly's Mounjaro and Zepbound [1] Group 2 - The defense sector in Europe also performed well, with a 1.2% increase, driven by a significant contract announcement from Norway to procure new frigates from the UK, valued at approximately £10 billion (about $13.51 billion) [1]

Core Viewpoint - Eli Lilly's Q2 performance exceeded market expectations, but disappointing results from oral GLP-1 drug trials led to a 13% drop in stock price [5][7]. Group 1: Financial Performance - Eli Lilly reported Q2 revenue of $15.56 billion, surpassing Wall Street's expectation of $14.69 billion; earnings per share were $6.31, above the forecast of $5.56 [5]. - U.S. market revenue reached $10.81 billion, with GLP-1 drugs Mounjaro and Zepbound seeing a 46% year-over-year sales increase, although an 8% price reduction limited revenue growth [5]. Group 2: Market Competition - Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in the competitive GLP-1 market, with Zepbound's prescription volume increasing by 225% year-over-year, totaling over 418,000 weekly prescriptions, compared to Wegovy's 35% increase and 281,000 weekly prescriptions [7]. - The oral GLP-1 drug orforglipron showed disappointing results in late-stage trials, with a 25% dropout rate in the highest dosage group, raising concerns about trial design [7]. Group 3: Future Outlook - Eli Lilly plans to submit data for orforglipron to the FDA this year, with hopes for approval and market entry next year [7]. - Novo Nordisk has lowered its 2025 outlook due to competitive pressures, while Eli Lilly holds over 60% of new weight loss prescriptions in the U.S. GLP-1 market [7][8].

Group 1 - The core viewpoint of the article highlights the strong performance of U.S. stock futures following the positive earnings reports from Microsoft and Meta, indicating a return of volatility in the market [1][3] - Microsoft shares rose by 9% in pre-market trading, approaching a market capitalization of $4 trillion, while Meta's shares surged by 11.13%, resulting in a combined market value increase of $537.6 billion for these two companies [1][3] - The S&P 500 index has experienced 25 consecutive trading days with price fluctuations not exceeding 1%, reflecting a period of low volatility prior to the recent earnings announcements [1] Group 2 - The U.S. June PCE price index showed a year-on-year increase of 2.6%, with the core PCE index rising by 2.8%, both figures exceeding market expectations [3] - The implementation of "Trump tariffs" is set to begin, with significant tariff rates of 35% and 30% on goods from Canada and Mexico, respectively, and a 25% tariff on Indian goods, potentially increasing inflationary pressures in the U.S. [4] - Ford has warned that its second-quarter earnings were impacted by $800 million due to tariffs, and the company has raised its full-year revenue impact estimate from tariffs to $3 billion [8] Group 3 - Moderna announced a 10% workforce reduction in response to declining vaccine sales, indicating financial pressures within the company [9] - Eli Lilly's long-term trial results for Mounjaro showed an 8% reduction in cardiovascular risks compared to Trulicity, but the market reaction was lukewarm, with shares initially dropping over 5% [10] - Anheuser-Busch InBev's stock fell over 10% in pre-market trading due to second-quarter sales declining more than expected, reflecting challenges in the beverage industry [11]